Summaries of health policy coverage from major news organizations
GlaxoSmithKline Ends Phase III Trial of AIDS Drug After Participant Develops Severe Liver Toxicity
GlaxoSmithKline has terminated enrollment for all of its Phase III trials of the experimental antiretroviral drug aplaviroc after a patient developed liver toxicity, Ono Pharmaceutical, which licensed the drug to GSK, announced on Tuesday, Reuters/Yahoo! Asia News reports (Reuters/Yahoo! Asia News, 10/25). Based on a review of data from its Phase IIb and Phase III studies, GSK intends to have all patients enrolled in any trial involving aplaviroc eventually stop taking the drug, according to a company statement (GSK release, 10/25). GSK last month suspended a trial of the drug after two HIV-positive participants developed similar liver problems. The two participants were among 250 HIV-positive volunteers in the trial -- which has sites in the U.S., Canada and the European Union -- who are newly diagnosed and who have never received treatment for HIV (Kaiser Daily HIV/AIDS Report, 9/19). The company said no other trials of the drug are planned (GSK release, 10/25).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.